Lentiviral vectors are efficient ex-vivo and in-vivo gene delivery systems for numerous cell and gene therapies such as chimeric antigen receptor (CAR)-T cell therapy. Like other live agents, lentiviral vectors are highly sensitive to their environment (pH, temperature, shear, chemical composition) and require a careful bioprocess.

Structured fixed-bed bioreactors offer a low-shear, well-controlled and homogeneous environment which achieves high productivity, high product quality, and cost-effectiveness in a reduced footprint. This webinar provides insights into:

  1. Existing challenges and solutions for lentiviral production.
  2. How a lentiviral specialist contract development and manufacturing organization (CDMO), VIVEbiotech, deploys the scale-X fixed-bed bioreactor from Univercells Technologies.
  3. Considerations for efficient process development and clinical lentivirus production.

Thank you very much to Univercells Technologies for always counting on us!

The webinar can be watched on demand here: https://globalmeet.webcasts.com/viewer/event.jsp?ei=1573372&tp_key=4378d60e1c